STOCK TITAN

Voyager Therapeutics Inc - VYGR STOCK NEWS

Welcome to our dedicated page for Voyager Therapeutics news (Ticker: VYGR), a resource for investors and traders seeking the latest updates and insights on Voyager Therapeutics stock.

Overview

Voyager Therapeutics Inc (VYGR) is a biotechnology company focused on developing innovative gene therapies for severe and debilitating diseases of the central nervous system (CNS). Using advanced AAV gene therapy techniques and its proprietary TRACER™ capsid discovery platform, Voyager is dedicated to overcoming traditional barriers in gene delivery and creating transformative solutions for neurological disorders.

Core Technology and Platform

The company leverages its TRACER™ (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) platform to engineer and optimize novel AAV capsids that are designed to cross the blood-brain barrier with high efficiency. This RNA-based screening enables rapid identification of capsid variants with enhanced CNS tropism and controlled tissue targeting, ensuring robust genetic payload delivery to areas of the brain traditionally hard to reach. The platform underpins both its gene therapy and antibody development programs, reflecting a robust integration of genetic science and neuroscience.

Pipeline and Disease Focus

Voyager Therapeutics maintains an extensive pipeline of programs aimed at addressing several critical CNS diseases. The company is developing gene therapy candidates to target conditions such as Parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (ALS), and Friedreich’s ataxia. Additionally, Voyager is advancing therapies aimed at modifying the pathological processes in Alzheimer’s disease through tau silencing and anti-tau antibodies. Each candidate is carefully designed to modulate protein expression in the CNS, aiming to slow disease progression and improve patient outcomes.

Research and Development Approach

Emphasizing rigorous process development and production scalability, Voyager invests heavily in vector optimization and sophisticated dosing techniques. The company conducts cross-species preclinical studies to ensure that its TRACER-generated capsids achieve widespread and efficient gene expression while minimizing off-target effects. Its commitment to scientific excellence is reflected in its strategic external collaborations, which not only validate its technology but also extend its reach within the neurogenetic medicines field.

Industry Significance and Competitive Position

Voyager Therapeutics distinguishes itself within the biotechnology landscape through its specialized focus on CNS diseases and its innovative AAV-based gene therapy solutions. By integrating cutting-edge gene editing methodologies with deep neuroscientific insights, the company fills a significant unmet need in neurological drug development. Its collaboration with established industry partners further underscores the scientific reliability, stringent development standards, and translational potential of its candidates. The company’s balanced portfolio and technology-driven approach position it as a critical contributor to the evolution of gene therapies for challenging neurological conditions.

Commitment to Innovation and Patient Impact

At the heart of Voyager Therapeutics’ mission is the goal of modifying the course of devastating neurological diseases. By focusing on durable gene expression attainable through a single administration, the company aims to provide long-lasting therapeutic benefits that can transform the quality of life for patients. Its efforts in process development and clinical standardization continue to set benchmarks within the field, reflecting a commitment to excellence that is both scientifically robust and patient-centered.

This comprehensive approach—encompassing advanced vector engineering, strategic collaborations, and meticulous clinical development—underscores Voyager Therapeutics’ prominence in the realm of neurogenetic medicines and offers a detailed perspective for investors and industry observers alike.

Rhea-AI Summary

Voyager Therapeutics (NASDAQ: VYGR) presented new preclinical data on a vectorized anti-tau antibody at the 24th Annual Meeting of the American Society of Gene and Cell Therapy. The data indicates durable expression within the central nervous system, which may provide a novel single-dose strategy for treating tauopathies like Alzheimer's. Key findings include a 59% reduction in tau pathology after intravenous administration in rodent models and lasting expression for at least 28 days. A virtual investor event is planned for July 2021 to discuss further developments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.59%
Tags
-
Rhea-AI Summary

Voyager Therapeutics (NASDAQ: VYGR) presented preclinical data at the 24th Annual Meeting of the American Society of Gene and Cell Therapy, showing significant advancements in gene therapy for neurological diseases. Their novel AAV capsids demonstrated up to 1000-fold higher transgene expression in the brain compared to traditional AAV therapy after intravenous administration. The lead candidate, TRACER 9P801, exhibited a favorable tolerability profile with no observed toxicity. This breakthrough underscores the potential for treating CNS disorders with lower doses than current AAV serotypes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.06%
Tags
none
-
Rhea-AI Summary

Voyager Therapeutics (VYGR) reported Q1 2021 financial results, highlighting progress in its Huntington's disease program, VY-HTT01. The FDA cleared its IND application, with plans to initiate a Phase 1/2 trial by Q4 2021. The company also developed novel AAV capsids that improve gene delivery. However, collaboration revenues dropped to $6.5 million from $18.1 million a year prior, with a net loss of $21.6 million. The company has $153.1 million in cash as of March 31, 2021, positioning itself for upcoming trials and innovations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.64%
Tags
Rhea-AI Summary

Voyager Therapeutics (Nasdaq: VYGR) announced significant data presentations at the ASGCT 24th Annual Meeting, scheduled for May 11-14, 2021. Key highlights include:

  • First reporting on novel capsid technology.
  • Oral presentations on RNA-driven AAV capsid evolution, anti-Tau antibody efficacy in mouse models, and capsid separation techniques.
  • Poster presentations on AAV gene therapy for chronic pain and AAV vector ultrafiltration.
  • Industry symposium on advancing AAV gene therapy for CNS diseases.

For more information, visit Voyager's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.17%
Tags
conferences
-
Rhea-AI Summary

Voyager Therapeutics (Nasdaq: VYGR) announced the FDA has lifted the clinical hold on its IND application for VY-HTT01, a gene therapy for Huntington’s disease. The therapy aims to reduce the expression of the huntingtin gene to alter disease progression. The Phase 1/2 clinical trial, named VYTAL, will evaluate the safety and tolerability of VY-HTT01 in early-stage HD patients. This trial is a crucial step as there are currently no approved disease-modifying therapies for HD, which affects over 30,000 individuals in the U.S. with debilitating symptoms.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.49%
Tags
none
-
Rhea-AI Summary

Voyager Therapeutics (NASDAQ: VYGR) has made significant progress in its lead program, VY-HTT01, for Huntington's disease, aiming to respond to FDA requests regarding its Investigational New Drug (IND) application by mid-2021. The company reported a fourth quarter 2020 net loss of $15.9 million, with total collaboration revenues of $6.5 million for the quarter, down from $32.7 million in Q4 2019. R&D expenses decreased to $22.0 million in Q4 2020, while cash and equivalents were $174.8 million as of December 31, 2020, expected to fund operations into mid-2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.99%
Tags
Rhea-AI Summary

Voyager Therapeutics (NASDAQ: VYGR) will announce its fourth quarter and full year 2020 financial results on February 25, 2021, after market close. A conference call is scheduled for 4:30 p.m. EST to discuss the results and provide a corporate update. Participants can access the call via a designated phone number or through a live webcast on the company's website. Additionally, Voyager will take part in the Cowen 41st Annual Health Care Conference on March 1, 2021 at 11:40 a.m. EST.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.35%
Tags
conferences earnings
-
Rhea-AI Summary

Voyager Therapeutics (NASDAQ: VYGR) has entered into an employment agreement providing inducement awards to a new employee. This includes a non-qualified stock option for 76,500 shares and restricted stock units for 13,000 shares. The stock option, effective January 11, 2021, has an exercise price of $8.43 per share. It vests over four years, while the restricted stock units vest annually over three years. These awards were approved by Voyager's Compensation Committee, aligning with Nasdaq regulations. Voyager focuses on gene therapy for severe neurological diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.08%
Tags
none
-
Rhea-AI Summary

Voyager Therapeutics (Nasdaq: VYGR) announced that the FDA has placed a clinical hold on the RESTORE-1 clinical trial for NBIb-1817 (VY-AADC), an investigational gene therapy for Parkinson's disease. This hold is due to MRI abnormalities observed in some trial participants, and additional patient data is required for review by the Data Safety Monitoring Board (DSMB) in early 2021. The trial had already been inactive due to COVID-19. Voyager and partner Neurocrine Biosciences are working with the FDA to address these concerns and determine the future course of the trial.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.53%
Tags
none
Rhea-AI Summary

Voyager Therapeutics (NASDAQ: VYGR) reported strong third-quarter 2020 results, highlighting significant collaboration revenues of $117.8 million, up from $20.4 million in Q3 2019. The company achieved a net income of $85.6 million, a turnaround from a $15.0 million loss last year. Research and development expenses decreased to $25.0 million from $29.8 million. Despite challenges, including clinical holds and a pause in trial enrollments, Voyager anticipates ending the year with $150-$170 million in cash and equivalents, sufficient for operations into mid-2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-23.21%
Tags

FAQ

What is the current stock price of Voyager Therapeutics (VYGR)?

The current stock price of Voyager Therapeutics (VYGR) is $3.09 as of April 4, 2025.

What is the market cap of Voyager Therapeutics (VYGR)?

The market cap of Voyager Therapeutics (VYGR) is approximately 168.7M.

What is the primary focus of Voyager Therapeutics?

Voyager Therapeutics is dedicated to developing gene therapies for severe neurological diseases using innovative AAV platforms and advanced vector engineering.

What is the TRACER™ platform?

The TRACER™ platform is an RNA-based screening technology that enables rapid discovery and optimization of AAV capsids for improved blood-brain barrier penetration and targeted CNS delivery.

Which central nervous system diseases does Voyager address?

Voyager’s pipeline includes therapies for Parkinson’s disease, amyotrophic lateral sclerosis (ALS), Friedreich’s ataxia, and Alzheimer’s disease, among other CNS conditions.

How does Voyager’s technology enhance gene delivery to the brain?

Their engineered AAV capsids are designed to cross the blood-brain barrier efficiently, target specific cell types, and achieve robust gene expression while limiting off-target transduction.

What distinguishes Voyager Therapeutics from other biotech companies?

Voyager is distinguished by its specialized focus on CNS diseases, its proprietary TRACER™ capsid discovery platform, and its commitment to integrating advanced gene therapy approaches with deep neuroscientific expertise.

Does Voyager collaborate with other organizations?

Yes, Voyager has strategic collaborations with established biotech firms, enhancing the scientific rigor and translational impact of its gene therapy candidates.

How do Voyager's therapies aim to impact patient treatment?

Their gene therapy candidates are designed to modify the underlying disease mechanisms by regulating protein expression, potentially slowing disease progression and improving patient quality of life.

What research methods support Voyager's development approach?

Voyager employs cross-species preclinical studies, advanced vector optimization, and robust process development to validate the safety and efficacy of its therapies.
Voyager Therapeutics Inc

Nasdaq:VYGR

VYGR Rankings

VYGR Stock Data

168.66M
45.58M
17%
63.9%
4.95%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
LEXINGTON